Close Menu

gene expression

A prospective study by a group of several primary care clinics and funded by CardioDx has found that CardioDx's coronary artery disease rule-out test, Corus CAD, significantly affected physician decision making in the primary care setting, changing doctors' treatment strategy for

Researchers from the University of South Florida and Agendia shared data this month that adds to a growing collection of evidence suggesting significant discordance between results of Agendia's MammaPrint and Genomic Health's Oncotype Dx breast cancer recurrence risk tests.

Researchers from Ohio State University have developed a score combining methylation and gene expression that proved a stronger predictor for the prognosis of acute myeloid leukemia patients than previously identified genetic markers.

A new study using gene expression profiling to divide patients from an adjuvant trastuzumab (Herceptin) clinical trial into subgroups based on their response to the drug has shown that adjuvant treatment in addition to chemotherapy might be effective even in HER2-negative patient

NEW YORK (GenomeWeb News) – NanoString Technologies said after the close of the market Tuesday that several US clinical laboratories will adopt the company's breast cancer assay starting in the first quarter of 2014.

NEW YORK (GenomeWeb News) – By folding genomic information about patients' lung cancer tumors in with other clinical data to inform treatment choice, patients generally exhibited improved survival, researchers from the

NEW YORK (GenomeWeb News) – Cardiovascular molecular diagnostics firm CardioDx, which plans to go public with an intended offering of up to $86.3 million, said that its revenues for the first

NEW YORK (GenomeWeb News) – Pacific Edge today announced it has signed on payor America's Choice Provider Network, expanding access to its bladder cancer test.

NEW YORK (GenomeWeb News) – Biosearch Technologies today announced it has acquired the exclusive worldwide rights to the turboFISH technology.

NEW YORK (GenomeWeb News) – Fluidigm and NanoString Technologies have settled lawsuits filed by Fluidigm that accused NanoString of false advertising, unfair competition, and unlawful trade practice, the companies announced after the close of the market on Tuesday.

Pages

As the Canadian election season heats up, neither major party has really paid much attention to science, according to Nature News.

BBC News says the uncertainty over Brexit is affecting science funding in the UK.

A new app purports to tell users "how gay" they are by looking at their DNA, but experts tell Futurism that the app is bunk.

In Nature this week: human and great ape cerebral organoids reveal aspects of brain development unique to humans, and more.